<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04097730</url>
  </required_header>
  <id_info>
    <org_study_id>18-26045</org_study_id>
    <secondary_id>UG1EY028518</secondary_id>
    <nct_id>NCT04097730</nct_id>
  </id_info>
  <brief_title>Steroids and Cross-linking for Ulcer Treatment</brief_title>
  <acronym>SCUT II</acronym>
  <official_title>Steroids and Cross-linking for Ulcer Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas M. Lietman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aravind Eye Care System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Steroids and Cross-linking for Ulcer Treatment (SCUT II) is an international, randomized,&#xD;
      double-masked, clinical trial. The purpose of this study is to determine differences in&#xD;
      6-month visual acuity between medical antimicrobial treatments alone versus antimicrobial&#xD;
      treatment plus collagen cross-linking (CXL), as well as to further evaluate findings from&#xD;
      subgroup analyses of SCUT. Patients presenting to the Aravind Eye Care System (India), Kaiser&#xD;
      Permanente Northern California (USA), or the University of California, San Francisco (USA)&#xD;
      with smear-positive and/or culture-positive typical (i.e. non-Nocardia or Mycobacteria)&#xD;
      bacterial corneal ulcers and moderate to severe vision loss, defined as Snellen visual acuity&#xD;
      of 20/40 or worse, will be eligible for inclusion. Those who agree to participate will be&#xD;
      randomized to one of three treatment groups:&#xD;
&#xD;
      Group 1: Standard therapy, topical 0.5% moxifloxacin plus topical placebo plus sham CXL Group&#xD;
      2: Early steroids, topical 0.5% moxifloxacin plus topical difluprednate 0.05% plus sham CXL&#xD;
      Group 3: CXL plus early steroids, topical 0.5% moxifloxacin plus topical difluprednate 0.05%&#xD;
      plus CXL&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Spectacle-Corrected Visual Acuity</measure>
    <time_frame>6 Months</time_frame>
    <description>Best Spectacle-Corrected Visual Acuity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Spectacle-Corrected Visual Acuity</measure>
    <time_frame>3 Weeks, 3 Months, 12 Months</time_frame>
    <description>Best Spectacle-Corrected Visual Acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Ulcers Testing Positive for Bacteria on Repeat Culture</measure>
    <time_frame>2 Days</time_frame>
    <description>Microbiological cure on repeat culture: A scraping of the corneal ulcer taken at 48 hours, then swabbed onto a culture plate and assessed for bacteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scar Size</measure>
    <time_frame>3 Weeks, 3 Months, 6 Months 12 Months</time_frame>
    <description>Geometric Mean</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scar Depth</measure>
    <time_frame>3 Weeks, 3 Months, 6 Months, 12 Months</time_frame>
    <description>Geometric Mean</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 Months</time_frame>
    <description>Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">279</enrollment>
  <condition>Keratitis Bacterial</condition>
  <arm_group>
    <arm_group_label>Standard Therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this arm will receive topical 0.5% moxifloxacin plus topical placebo plus sham corneal cross-linking.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early Steroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive topical 0.5% moxifloxacin plus topical steroids plus sham corneal cross-linking.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cross-Linking plus Early Steroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive topical 0.5% moxifloxacin plus topical steroids plus corneal cross-linking.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin Ophthalmic</intervention_name>
    <description>Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is standard therapy for bacterial keratitis. Immediately after CXL/sham CXL and repeat culture, all participants will receive topical moxifloxacin drops every 1 hour for 2 days, and then every 2 hours while awake until resolution of the epithelial defect.</description>
    <arm_group_label>Cross-Linking plus Early Steroids</arm_group_label>
    <arm_group_label>Early Steroids</arm_group_label>
    <arm_group_label>Standard Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Difluprednate Ophthalmic</intervention_name>
    <description>Difluprednate 0.05% is a corticosteroid used to reduce inflammation in the eye. Participants will receive one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of steroid therapy.</description>
    <arm_group_label>Cross-Linking plus Early Steroids</arm_group_label>
    <arm_group_label>Early Steroids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riboflavin Ophthalmic</intervention_name>
    <description>All participants will receive a 30 minute loading dose of topical 0.1% riboflavin and 20% dextran T500 drops every 2 minutes. For participants randomized to corneal cross-linking(CXL), this will be followed by exposure to UV-A light at a wavelength of 365 nm with an irradiance of 3 mW/cm2 for 30 minutes for a total dose of 5.4 J/cm2 (UV lamp: PESCHKE Meditrade GmbH, Hueneberg, Switzerland for India; Avedro KXL System, Waltham, MA, USA for USA). During irradiation patients will continue to receive topical riboflavin at 5-minute intervals. For those randomized to sham CXL, this experience is simulated however the light will be shined adjacent to the patient, careful to avoid exposure to the cornea.</description>
    <arm_group_label>Cross-Linking plus Early Steroids</arm_group_label>
    <arm_group_label>Standard Therapy</arm_group_label>
    <other_name>Corneal Cross-Linking with Riboflavin Ophthalmic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Topical Placebo</intervention_name>
    <description>Participants randomized to topical placebo will receive topical placebo on the same medication schedule as difluprednate: one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of placebo therapy. Placebo will be the vehicle used in difluprednate.</description>
    <arm_group_label>Standard Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Corneal ulcer that is smear positive and/or culture positive (within 24 hours) for&#xD;
             typical bacteria (i.e. non-Nocardia or Mycobacteria)&#xD;
&#xD;
          -  Moderate to severe vision loss, defined as Snellen visual acuity of 20/40 (6/12) or&#xD;
             worse&#xD;
&#xD;
          -  Corneal thickness ≥350 µm, as measured on AS-OCT&#xD;
&#xD;
          -  Age over 18 years&#xD;
&#xD;
          -  Basic understanding of the study as determined by the physician&#xD;
&#xD;
          -  Commitment to return for follow up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of concomitant infection on exam, gram stain, or confocal microscopy (i.e.&#xD;
             herpes, both bacteria and acanthameoba on gram stain)&#xD;
&#xD;
          -  Impending or frank perforation at recruitment&#xD;
&#xD;
          -  Involvement of sclera at presentation&#xD;
&#xD;
          -  Non-infectious or autoimmune keratitis&#xD;
&#xD;
          -  History of corneal transplantation or recent intraocular surgery&#xD;
&#xD;
          -  Pinhole visual acuity worse than 20/200 in the unaffected eye&#xD;
&#xD;
          -  Participants who are decisionally and/or cognitively impaired&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Lietman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer Rose-Nussbaumer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicole Varnado, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tom Lietman, MD</last_name>
    <phone>415-502-2662</phone>
    <email>tom.lietman@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Varnado, MPH</last_name>
    <email>nvarnado@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Francis I. Proctor Foundaiton</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Lietman, MD</last_name>
      <phone>415-502-2662</phone>
      <email>tom.lietman@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Victoria Cavallino, MSPH</last_name>
      <phone>619.540.6557</phone>
      <email>victoria.cavallino@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gerami Seitzman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillermo Amescua, MD</last_name>
      <phone>305-243-2020</phone>
      <email>GAmescua@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anibal Munguia</last_name>
      <phone>(305) 482-5051</phone>
      <email>amm7350@med.miami.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Aravind Eye Care System</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>N.V. Prajna</last_name>
      <email>prajna@aravind.org</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 12, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Thomas M. Lietman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Difluprednate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

